Disease Models & Mechanisms | The Company of Biologists

Skip Nav Destination

Disease Models & Mechanisms (DMM) is an Open Access biomedical research journal advancing novel insight into the mechanism, diagnosis and therapy of human disease.

DMM is committed to publishing rigorously peer-reviewed research in disease biology that has significant translational impact at the interface of basic and clinical science. Our content is freely available to our communities of basic and clinical researchers, health professionals, patients and their advocates and families. DMM is interdisciplinary in scope, and covers a diverse range of diseases. We also publish cutting-edge techniques and resources that advance the disease biology field.

DMM is led by an international team of expert research-active Editors, including Editor-in-Chief Liz Patton and Deputy Editor-in-Chief Elaine Mardis, and supported by an outstanding Editorial Advisory Board.

DMM included in Read & Publish agreements

From 2022, DMM is included in many of the Read & Publish agreements offered by The Company of Biologists. This enables discounted or fee-free publication of an uncapped number of Research articles in DMM for corresponding authors at participating institutions (including, among others, the Max Planck Digital Library and University of California).

Read more about the ways in which DMM is working to increase accessibility for both authors and readers in an Editorial from Editor-in-Chief Liz Patton.

Call for papers for Special Issue

DMM invites you to submit your latest research for our upcoming special issue: Moving Heart Failure to Heart Success: Mechanisms, Regeneration & Therapy. This issue will be coordinated by guest editors Jeroen Bakkers (Hubrecht Institute, The Netherlands), Milena Bellin (Department of Biology, University of Padova, Italy, and Leiden University Medical Center, The Netherlands) and Ravi Karra (Duke University School of Medicine, USA).

The deadline for submitting articles to the special issue has been extended to Monday 1 August 2022.

Find out more about how to submit.

Perspective

How inclusive are cell lines in preclinical engineered cancer models?

Shreya Raghavan discusses how genetic determinants, such as ancestry, impact cancer risk and therapeutic outcomes, and hence are important to consider at the very initial stages of biomedical research at the bench.

Joan Heath interviews Suzanne Cory and Joan Steitz: a female perspective of science in the swinging ‘60s

Prompted by the occasion of International Women's Day, Joan Heath and DMM reunited Professors Suzanne Cory and Joan Steitz via Zoom to discuss their extraordinary careers and joint experiences in science. They also delve into past and present challenges for women in science, and discuss the role of scientists in a post-pandemic world.

Editor's Choice

Gupta and colleagues conducted the first study of lung transcriptomes from severe COVID-19 patients in an Indian population. Transcriptome data revealed vast differences in host gene expression, cell type composition and microbial signatures between lung tissue samples from patients with severe COVID-19 and control patients. Two distinct molecular signatures within the COVID-19 patient group also emerged.

Clinical Puzzle

Dissecting the phenotypic variability of osteogenesis imperfecta

Forlino and colleagues analysed the largest public osteogenesis imperfecta (OI) database, as well as data from animal models, to address how type I collagen defects contribute to the phenotypic variability of the brittle bone disease OI.